Suberoylanilide hydroxamic acid induces viral lytic cycle in Epstein-Barr virus-positive epithelial malignancies and mediates enhanced cell death

International Journal of Cancer

Volumn 126, Issue 10, 2010, Pages 2479-2489

  Hui, K F ^a   Chiang, Alan K S ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Epithelial cancer; Epstein Barr virus; Histone deacetylase inhibitor; Lytic cycle; Suberoylanilide hydroxamic acid

Indexed keywords

BUTYRIC ACID; TRICHOSTATIN A; VALPROIC ACID; VIRUS DNA; VIRUS PROTEIN; VORINOSTAT; ANTINEOPLASTIC AGENT; BUTYRIC ACID DERIVATIVE; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID;

ARTICLE; BURKITT LYMPHOMA; CARCINOMA; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CONTROLLED STUDY; DNA REPLICATION; EPSTEIN BARR VIRUS; HUMAN; HUMAN CELL; LYMPHOBLASTOID CELL; NASOPHARYNX CARCINOMA; PRIORITY JOURNAL; STOMACH CARCINOMA; VIRUS INFECTIVITY; VIRUS PARTICLE; VIRUS REPLICATION; APOPTOSIS; CELL CYCLE; CELL SURVIVAL; DRUG EFFECT; FLUORESCENT ANTIBODY TECHNIQUE; LEUKEMIA; POLYMERASE CHAIN REACTION; STOMACH TUMOR; TUMOR CELL LINE; VIROLOGY; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; BURKITT LYMPHOMA; BUTYRATES; CARCINOMA; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; FLUORESCENT ANTIBODY TECHNIQUE; HERPESVIRUS 4, HUMAN; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; LEUKEMIA; POLYMERASE CHAIN REACTION; STOMACH NEOPLASMS; VALPROIC ACID;

EID: 77951209628     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24945     Document Type: Article

References (35)

1. Rickinson AB, Kieff E. Epstein-Barr virus and its replication. In: Knipe DM, Howley PM. Fields virology, 5th edn. Philadelphia: Lippincott Williams and Wilkins, 2007.2604-2654
2. Amon W, Farrell PJ. Reactivation of Epstein-Barr virus from latency. Rev Med Virol 2004;15:149-156
3. Chiang AK, Tao Q, Srivastava G, Ho FC. Nasal NK- and T-cell lymphomas share the same type of Epstein-Barr virus latency as nasopharyngeal carcinoma and Hodgkin's disease. Int J Cancer 1996;68:285-290 (Pubitemid 26384128)
4. Thompson MP, Kurzrock R. Epstein-Barr virus and cancer. Clin Cancer Res 2004;10:803-821
5. Feng WH, Hong G, Delecluse HJ, Kenney SC. Lytic induction therapy for Epstein-Barr virus-positive B-cell lymphomas. J Virol 2004;78:1893-1902 (Pubitemid 38176721)
6. Feng WH, Israel B, Raab-Traub N, Busson P, Kenney SC. Chemotherapy induces lytic EBV replication and confers ganciclovir susceptibility to EBV-positive epithelial cell tumors. Cancer Res 2002;62:1920-1926 (Pubitemid 34408523)
7. Fahmi H, Cochet C, Hmama Z, Opolon P, Joab I. Transforming growth factor beta 1 stimulates expression of the Epstein-Barr virus BZLF1 immediate-early gene product ZEBRA by an indirect mechanism which requires the MAPK kinase pathway. J Virol 2000;74:5810-5818 (Pubitemid 30412948)
8. Gradoville L, Kwa D, El-Guindy A, Miller G. Protein kinase C-independent activation of the Epstein-Barr virus lytic cycle. J Virol 2002;76:5612-5626 (Pubitemid 34517912)
9. Feng W-H, Kenney SC. Valproic acid enhances the efficacy of chemotherapy in EBV-positive tumors by increasing lytic viral gene expression. Cancer Res 2006;66:8762-8769
10. Moore SM, Cannon JS, Tanhehco YC, Hamzeh FM, Ambinder RF. Induction of Epstein-Barr virus kinases to sensitize tumor cells to nucleoside analogues. Antimicrob Agents Chemother 2001;45:2082-2091
11. Westphal EM, Blackstock W, Feng W, Israel B, Kenney SC. Activation of lytic Epstein-Barr virus (EBV) infection by radiation and sodium butyrate in vitro and in vivo: a potential method for treating EBV-positive malignancies. Cancer Res 2000;60:5781-5788
12. Nutter LM, Grill SP, Li JS, Tan RS, Cheng YC. Induction of virus enzymes by phorbol esters and n-butyrate in Epstein-Barr virus genome-carrying Raji cells. Cancer Res 1987;47:4407-4412
13. Xu WS, Parmigiani RB, Marks PA. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 2007;26:5541-5552 (Pubitemid 47255934)
14. Murphy JC, Fischle W, Verdin E, Sinclair JH. Control of cytomegalovirus lytic gene expression by histone acetylation. EMBO J 2002;21:1112-1120 (Pubitemid 34206184)
15. Chang LK, Liu ST. Activation of the BRLF1 promoter and lytic cycle of Epstein-Barr virus by histone acetylation. Nucleic Acids Res 2000;28:3918-3925
16. Vansteenkiste J, van Cutsem E, Dumez H, Chen C, Ricker JL, Randolph SS, Schoffski P. Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer. Invest New Drugs 2008;26:483-488
17. Munster PN, Troso-Sandoval T, Rosen N, Rifkind R, Marks PA, Richon VM. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. Cancer Res 2001;61:8492-8497 (Pubitemid 33131130)
18. Richon VM, Zhou X, Rifkind RA, Marks PA. Histone deacetylase inhibitors: development of suberoylanilide hydroxamic acid (SAHA) for the treatment of cancers. Blood Cells Mol Dis 2001;27:260-264 (Pubitemid 32299781)
19. Buglio D, Georgakis GV, Hanabuchi S, Arima K, Khaskhely NM, Liu YJ, Younes A. Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines. Blood 2008;112:1424-1433
20. Amon W, Binne UK, Bryant H, Jenkins PJ, Karstegl CE, Farrell PJ. Lytic cycle gene regulation of Epstein-Barr virus. J Virol 2004;78:13460-13469 (Pubitemid 39612746)
21. Molesworth SJ, Lake CM, Borza CM, Turk SM, Hutt-Fletcher LM. Epstein-Barr virus gH is essential for penetration of B cells but also plays a role in attachment of virus to epithelial cells. J Virol 2000;74:6324-6332
22. Lui VW, Wong EY, Ho Y, Hong B, Wong SC, Tao Q, Choi GC, Au TC, Ho K, Yau DM, Ma BB, Hui EP, et al. STAT3 activation contributes directly to Epstein-Barr virus-mediated invasiveness of nasopharyngeal cancer cells in vitro. Int J Cancer 2009;125:1884-1893
23. Drexler HG, Matsuo Y. Malignant hematopoietic cell lines: in vitro models for the study of natural killer cell leukemia-lymphoma. Leukemia 2000;14:777-782 (Pubitemid 30235051)
24. Chang SS, Lo YC, Chua HH, Chiu HY, Tsai SC, Chen JY, Lo KW, Tsai CH. Critical role of p53 in histone deacetylase inhibitor-induced Epstein-Barr virus Zta expression. J Virol 2008;82:7745-7751
25. Fang CY, Lee CH, Wu CC, Chang YT, Yu SL, Chou SP, Huang PT, Chen CL, Hou JW, Chang Y, Tsai CH, Takada K, et al. Recurrent chemical reactivations of EBV promotes genome instability and enhances tumor progression of nasopharyngeal carcinoma cells. Int J Cancer 2009;124:2016-2025
26. Huang J, Liao G, Chen H, Wu FY, Hutt- Fletcher L, Hayward GS, Hayward SD. Contribution of C/EBP Proteins to Epstein-Barr virus lytic gene expression and replication in epithelial cells. J Virol 2006;80:1098-1109 (Pubitemid 43134067)
27. Marks PA. Discovery and development of SAHA as an anticancer agent. Oncogene 2007;26:1351-1356
28. Klass CM, Krug LT, Pozharskaya VP, Offermann MK. The targeting of primary effusion lymphoma cells for apoptosis by inducing lytic replication of human herpesvirus 8 while blocking virus production. Blood 2005;105:4028-4034
29. Rodriguez A, Jung EJ, Flemington EK. Cell cycle analysis of Epstein-Barr virus-infected cells following treatment with lytic cycleinducing agents. J Virol 2001;75:4482-4489 (Pubitemid 32381490)
30. Floettmann JE, Ward K, Rickinson AB, Rowe M. Cytostatic effect of Epstein-Barr virus latent membrane protein-1 analyzed using tetracycline- regulated expression in B cell lines. Virology 1996;223:29-40. (Pubitemid 26302043)
31. Krauer KG, Burgess A, Buck M, Flanagan J, Sculley TB, Gabrielli B. The EBNA-3 gene family proteins disrupt the G2/M checkpoint. Oncogene 2004;23:1342-1353 (Pubitemid 38406830)
32. Flemington EK. Herpesvirus lytic replication and the cell cycle: arresting new developments. J Virol 2001;75:4475-4481
33. Mauser A, Holley-Guthrie E, Simpson D, Kaufmann W, Kenney S. The Epstein-Barr virus immediate-early protein BZLF1 induces both a G(2) and a mitotic block. J Virol 2002;76:10030-10037 (Pubitemid 35006543)
34. Mauser A, Holley-Guthrie E, Zanation A, Yarborough W, Kaufmann W, Klingelhutz A, Seaman WT, Kenney S. The Epstein-Barr virus immediate-early protein BZLF1 induces expression of E2F-1 and other proteins involved in cell cycle progression in primary keratinocytes and gastric carcinoma cells. J Virol 2002;76:12543-12552 (Pubitemid 35386940)
35. Jung EJ, Lee YM, Lee BL, Chang MS, Kim WH. Lytic induction and apoptosis of Epstein-Barr virus-associated gastric cancer cell line with epigenetic modifiers and ganciclovir. Cancer Lett 2007;247:77-83. (Pubitemid 44959412)